항생제 주입 요법 시장 규모, 점유율, 동향 및 성장 분석 보고서(2026-2034년)

The global antibiotic infusion therapy market size is expected to reach USD 65.43 Billion in 2034 from USD 37.95 Billion in 2025, growing at a CAGR of 6.24% during 2026-2034.This market is expanding as hospitals and healthcare providers continue to require effective intravenous antibiotic treatment for serious bacterial infections. Antibiotic infusion therapy is particularly important for patients who cannot take oral medications or require rapid and controlled delivery of antimicrobial agents. Increasing hospitalization rates associated with severe infections, complex surgical procedures, and chronic illnesses are supporting demand. Home-based infusion services are also contributing to market development by enabling selected patients to continue treatment outside traditional hospital settings.

Growth is driven by the increasing prevalence of complicated infections, demand for targeted antimicrobial treatment, and advances in infusion technologies. Hospitals are adopting programmable infusion pumps and advanced drug-delivery systems to improve dosing accuracy and patient safety. Outpatient parenteral antimicrobial therapy is also gaining importance because it can reduce hospital stays and healthcare costs when clinically appropriate. At the same time, antimicrobial stewardship programs are encouraging healthcare providers to use antibiotics more carefully and select therapies according to infection characteristics and patient needs.

Future prospects will depend on balancing continued demand for intravenous antibiotics with global efforts to address antimicrobial resistance. Development of more targeted therapies, improved diagnostics, and smarter infusion systems could support safer and more effective treatment. Home infusion and outpatient care models are expected to gain further adoption as healthcare systems seek cost-efficient treatment pathways. Digital monitoring, connected infusion devices, and personalized treatment protocols may also create new opportunities while improving adherence, clinical oversight, and overall patient management.

Our reports are carefully developed to deliver comprehensive and actionable insights across a wide range of industries and markets. Each report includes several essential components designed to provide a complete understanding of the market environment:

Market Overview: This section provides a clear introduction to the market, including key definitions, classifications, and an overview of the current industry landscape.

Market Dynamics: A detailed evaluation of the primary drivers, restraints, opportunities, and challenges shaping market growth. It covers factors such as technological developments, regulatory frameworks, and evolving industry trends.

Segmentation Analysis: A structured breakdown of the market into key segments based on product type, application, end-user, and geographic region. This section highlights the performance, growth potential, and contribution of each segment.

Competitive Landscape: An in-depth assessment of leading market participants, including their market positioning, product portfolios, strategic initiatives, and financial performance. It provides valuable insights into competitive dynamics and the strategies adopted by key players.

Market Forecast: Data-driven projections of market size and growth patterns over a defined forecast period. This section incorporates historical trends, current market conditions, and quantitative analysis to illustrate expected future developments.

Regional Analysis: A comprehensive review of market performance across major geographic regions, identifying high-growth areas and regional trends to better understand localized market opportunities.

Emerging Trends and Opportunities: Identification of significant market trends, technological advancements, and new investment opportunities. This section highlights potential growth areas and future industry developments.

Customization Options: We offer flexible customization services to tailor reports according to specific client requirements. This may include additional segmentation, country-level analysis, competitor profiling, customized data points, or focused insights on particular market segments to better support strategic decision-making.

MARKET SEGMENTATION

By Product

• Drugs
• Devices
• Services

By Antibiotics Class

• Cephalosporins
• Carbapenems
• Glycopeptides
• Penicillins & Beta-lactam/Beta-lactamase Inhibitor Combinations
• Aminoglycosides
• Oxazolidinones & Lipopeptides
• Others

By Indication

• Bloodstream Infections & Sepsis
• Respiratory Tract Infections
• Skin & Soft Tissue Infections
• Urinary Tract & Intra-abdominal Infections
• Bone & Joint Infections
• Others

By Age Group

• Adults
• Pediatric

By Setting

• Hospitals
• Outpatient Infusion Centers
• Home Infusion
• Others

COMPANIES PROFILED

• Pfizer Inc., Fresenius Kabi AG, Sandoz Inc., Baxter International Inc., B. Braun SE, BD, ICU Medical Inc., Terumo Corporation, Option Care Health Inc., KabaFusion, Soleo Health, CVS Health, Cencora Inc., McKesson Corporation, Cardinal Health, PharMerica, InfuSystem Holdings

TABLE OF CONTENTS

Chapter 1. PREFACE

• 1.1. Market Segmentation & Scope
• 1.2. Market Definition
• 1.3. Information Procurement
  • 1.3.1 Information Analysis
  • 1.3.2 Market Formulation & Data Visualization
  • 1.3.3 Data Validation & Publishing
• 1.4. Research Scope and Assumptions
  • 1.4.1 List of Data Sources

Chapter 2. EXECUTIVE SUMMARY

• 2.1. Market Snapshot
• 2.2. Segmental Outlook
• 2.3. Competitive Outlook

Chapter 3. MARKET VARIABLES, TRENDS, FRAMEWORK

• 3.1. Market Lineage Outlook
• 3.2. Penetration & Growth Prospect Mapping
• 3.3. Value Chain Analysis
• 3.4. Regulatory Framework
  • 3.4.1 Standards & Compliance
  • 3.4.2 Regulatory Impact Analysis
• 3.5. Market Dynamics
  • 3.5.1 Market Drivers
  • 3.5.2 Market Restraints
  • 3.5.3 Market Opportunities
  • 3.5.4 Market Challenges
• 3.6. Porter's Five Forces Analysis
• 3.7. PESTLE Analysis

Chapter 4. GLOBAL ANTIBIOTIC INFUSION THERAPY MARKET: BY PRODUCT 2022-2034 (USD MN)

• 4.1. Market Analysis, Insights and Forecast Product
• 4.2. Drugs Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 4.3. Devices Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 4.4. Services Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 5. GLOBAL ANTIBIOTIC INFUSION THERAPY MARKET: BY ANTIBIOTICS CLASS 2022-2034 (USD MN)

• 5.1. Market Analysis, Insights and Forecast Antibiotics Class
• 5.2. Cephalosporins Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.3. Carbapenems Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.4. Glycopeptides Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.5. Penicillins & Beta-lactam/Beta-lactamase Inhibitor Combinations Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.6. Aminoglycosides Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.7. Oxazolidinones & Lipopeptides Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.8. Others Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 6. GLOBAL ANTIBIOTIC INFUSION THERAPY MARKET: BY INDICATION 2022-2034 (USD MN)

• 6.1. Market Analysis, Insights and Forecast Indication
• 6.2. Bloodstream Infections & Sepsis Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 6.3. Respiratory Tract Infections Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 6.4. Skin & Soft Tissue Infections Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 6.5. Urinary Tract & Intra-abdominal Infections Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 6.6. Bone & Joint Infections Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 6.7. Others Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 7. GLOBAL ANTIBIOTIC INFUSION THERAPY MARKET: BY AGE GROUP 2022-2034 (USD MN)

• 7.1. Market Analysis, Insights and Forecast Age Group
• 7.2. Adults Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 7.3. Pediatric Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 8. GLOBAL ANTIBIOTIC INFUSION THERAPY MARKET: BY SETTING 2022-2034 (USD MN)

• 8.1. Market Analysis, Insights and Forecast Setting
• 8.2. Hospitals Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 8.3. Outpatient Infusion Centers Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 8.4. Home Infusion Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 8.5. Others Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 9. GLOBAL ANTIBIOTIC INFUSION THERAPY MARKET: BY REGION 2022-2034 (USD MN)

• 9.1. Regional Outlook
• 9.2. North America Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 9.2.1 By Product
  • 9.2.2 By Antibiotics Class
  • 9.2.3 By Indication
  • 9.2.4 By Age Group
  • 9.2.5 By Setting
  • 9.2.6 United States
  • 9.2.7 Canada
  • 9.2.8 Mexico
• 9.3. Europe Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 9.3.1 By Product
  • 9.3.2 By Antibiotics Class
  • 9.3.3 By Indication
  • 9.3.4 By Age Group
  • 9.3.5 By Setting
  • 9.3.6 United Kingdom
  • 9.3.7 France
  • 9.3.8 Germany
  • 9.3.9 Italy
  • 9.3.10 Spain
  • 9.3.11 Russia
  • 9.3.12 Rest Of Europe
• 9.4. Asia-Pacific Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 9.4.1 By Product
  • 9.4.2 By Antibiotics Class
  • 9.4.3 By Indication
  • 9.4.4 By Age Group
  • 9.4.5 By Setting
  • 9.4.6 China
  • 9.4.7 Japan
  • 9.4.8 South Korea
  • 9.4.9 India
  • 9.4.10 Australia
  • 9.4.11 South East Asia
  • 9.4.12 Rest Of Asia Pacific
• 9.5. Latin America Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 9.5.1 By Product
  • 9.5.2 By Antibiotics Class
  • 9.5.3 By Indication
  • 9.5.4 By Age Group
  • 9.5.5 By Setting
  • 9.5.6 Brazil
  • 9.5.7 Argentina
  • 9.5.8 Peru
  • 9.5.9 Chile
  • 9.5.10 Rest of Latin America
• 9.6. Middle East & Africa Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 9.6.1 By Product
  • 9.6.2 By Antibiotics Class
  • 9.6.3 By Indication
  • 9.6.4 By Age Group
  • 9.6.5 By Setting
  • 9.6.6 Saudi Arabia
  • 9.6.7 UAE
  • 9.6.8 Israel
  • 9.6.9 South Africa
  • 9.6.10 Rest of the Middle East And Africa

Chapter 10. COMPETITIVE LANDSCAPE

• 10.1. Recent Developments
• 10.2. Company Categorization
• 10.3. Supply Chain & Channel Partners (based on availability)
• 10.4. Market Share & Positioning Analysis (based on availability)
• 10.5. Vendor Landscape (based on availability)
• 10.6. Strategy Mapping

Chapter 11. COMPANY PROFILES OF GLOBAL ANTIBIOTIC INFUSION THERAPY INDUSTRY

• 11.1. Top Companies Market Share Analysis
• 11.2. Company Profiles
  • 11.2.1 Pfizer Inc
  • 11.2.2 Fresenius Kabi AG
  • 11.2.3 Sandoz Inc
  • 11.2.4 Baxter International Inc
  • 11.2.5 B. Braun SE
  • 11.2.6 BD
  • 11.2.7 ICU Medical Inc
  • 11.2.8 Terumo Corporation
  • 11.2.9 Option Care Health Inc
  • 11.2.10 KabaFusion
  • 11.2.11 Soleo Health
  • 11.2.12 CVS Health
  • 11.2.13 Cencora Inc
  • 11.2.14 McKesson Corporation
  • 11.2.15 Cardinal Health
  • 11.2.16 PharMerica
  • 11.2.17 InfuSystem Holdings